Despite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as one of the most promising target antigens. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM. Data on more than 300 MM patients treated with anti-BCMA directed CAR T cells are available and these numbers are rapidly increasing. The response rate and the depth of responses induced by anti-BCMA CAR T cells are impressive; however, the majority of patients eventually relapse. Understanding the underlying mechanisms of response and resistance in treated MM patients will be critical to the rational development of this therapy. Moreover, the ideal place of this therapy in the treatment paradigm for MM is an important question that needs biological and clinical correlative data to help elucidate. T-cell-related, tumor-related and microenvironmental factors may play a role in the efficacy of anti-BCMA CAR T-cell therapy. In this review we summarize key clinical and correlative data on anti-BCMA CAR T-cell therapy. Based on available data we will try to highlight opportunities to further optimize this potential game-changing therapy for MM.

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

D'Agostino M.
First
;
2020-01-01

Abstract

Despite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as one of the most promising target antigens. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM. Data on more than 300 MM patients treated with anti-BCMA directed CAR T cells are available and these numbers are rapidly increasing. The response rate and the depth of responses induced by anti-BCMA CAR T cells are impressive; however, the majority of patients eventually relapse. Understanding the underlying mechanisms of response and resistance in treated MM patients will be critical to the rational development of this therapy. Moreover, the ideal place of this therapy in the treatment paradigm for MM is an important question that needs biological and clinical correlative data to help elucidate. T-cell-related, tumor-related and microenvironmental factors may play a role in the efficacy of anti-BCMA CAR T-cell therapy. In this review we summarize key clinical and correlative data on anti-BCMA CAR T-cell therapy. Based on available data we will try to highlight opportunities to further optimize this potential game-changing therapy for MM.
2020
34
1
21
34
https://www.nature.com/articles/s41375-019-0669-4
https://doi.org/10.1038/s41375-019-0669-4
B-Cell Maturation Antigen; Humans; Immunotherapy, Adoptive; Multiple Myeloma; Receptors, Chimeric Antigen
D'Agostino M.; Raje N.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] D'Agostino and Raje - 2020 - Leukemia - s41375-019-0669-4.pdf

Accesso riservato

Descrizione: [Restricted access - Published vsn.] D'Agostino M and Raje N. Leukemia . 2020 Jan;34(1):21-34. doi: 10.1038/s41375-019-0669-4. Epub 2019 Nov 28. PMID: 31780814. © The Author(s), under exclusive licence to Springer Nature Limited 2019. Available at: https://www.nature.com/articles/s41375-019-0669-4 | https://doi.org/10.1038/s41375-019-0669-4
Tipo di file: PDF EDITORIALE
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1791001
Citazioni
  • ???jsp.display-item.citation.pmc??? 66
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 102
social impact